Product nameAnti-Alpha-synuclein (phospho Y125) antibody
See all Alpha-synuclein primary antibodies
DescriptionRabbit polyclonal to Alpha-synuclein (phospho Y125)
Tested applicationsSuitable for: WB, ELISA, IHC-FoFr, ICC/IFmore details
Species reactivityReacts with: Rat, Recombinant fragment
Predicted to work with: Mouse, Human
Synthetic peptide corresponding to Human Alpha-synuclein aa 100 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Corresponding Unmodified Peptide
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab10789 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Detects a band of approximately 15 kDa (predicted molecular weight: 14 kDa).Can be blocked with Human Alpha-synuclein (phospho Y125) peptide (ab17030).|
|ELISA||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration. PubMed: 21114836|
FunctionMay be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
Tissue specificityExpressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
Involvement in diseaseGenetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Parkinson disease 1
Parkinson disease 4
Dementia Lewy body
Sequence similaritiesBelongs to the synuclein family.
DomainThe 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
modificationsPhosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
Cellular localizationCytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
- Information by UniProt
- Alpha synuclein antibody
- Alpha-synuclein antibody
- Alpha-synuclein, isoform NACP140 antibody
All lanes : Anti-Alpha-synuclein (phospho Y125) antibody (ab10789) at 1/1000 dilution
Lane 1 : Negative control cells harboring empty vector
Lane 2 : alpha synuclein expressed in Saccharomyces cerevisiae, strain BY4741 at 10 µg
Lane 3 : A30P-synuclein expressed in Saccharomyces cerevisiae, strain BY4741 at 10 µg/ml
All lanes : HRP-conjugated goat anti-rabbit IgG polyclonal at 1/5000 dilution
Developed using the ECL technique.
Performed under non-reducing conditions.
Predicted band size: 14 kDa
Observed band size: 15 kDa why is the actual band size different from the predicted?
Additional bands at: 37 kDa (possible non-specific binding), 55 kDa (possible non-specific binding)
Exposure time: 3 minutes
Proteins purified by Ni2+-NTA pull-down.
IHC-FoFr image of ab10789 (1:100) staining on Rat brain sections. Images show staining of alpha synuclein (phospho Y125) in Hippocampus (Top Left), Hypothalamus (Top Centre) and Cortex (Top Right). Peptide pre-absorbtion was performed with the antibody to determine specificity to the modification on rat hippocampus sections. The antibody was incubated with No Peptide (Bottom Left), Unmodified peptide (Bottom Centre) and Modified Peptide (Bottom Right).
This product has been referenced in:
- Vicente Miranda H et al. Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Sci Rep 7:13713 (2017). Read more (PubMed: 29057912) »
- Kiely AP et al. a-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 125:753-69 (2013). ICC/IF ; Human . Read more (PubMed: 23404372) »